Abstract
Background and AimsThe Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus (RSV) hospitalizations in high-risk infants including 186 with cystic fibrosis (CF). This study compares respiratory...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Archives of disease in childhood. Fetal and neonatal edition
Paper Title
Journal
Date
